ACE Inhibitor, Angiotensin II Receptor Antagonist, Monotherapy or Combined Therapy?

Publisher： Karger

E-ISSN： 1424-0556|4|3|145-150

ISSN： 1422-9528

Source： Heart Drug, Vol.4, Iss.3, 2004-08, pp. : 145-150

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

ACE Inhibitor and Angiotensin II Type 1 Receptor Antagonist Therapies in Elderly Patients with Diabetes Mellitus: Are They Underutilized?

By > Winkelmayer Wolfgang C.

Drugs & Aging, Vol. 27, Iss. 2, 2010-02 ,pp. : 87-94

Adis International

Access to resources Recommend Favorite

Effect on the Atherogenic Marker Plasminogen Activator Inhibitor Type-1 of Addition of the ACE Inhibitor Imidapril to Angiotensin II Type 1 Receptor Antagonist Therapy in Hypertensive Patients with Abnormal Glucose Metabolism: A Prospective Cohort Study in Primary Care

By Yajima Ken Shimada Akira

Clinical Drug Investigation, Vol. 29, Iss. 12, 2009-12 ,pp. : 811-819

Adis International

Access to resources Recommend Favorite

Which Strategy Is More Effective for the Treatment of Cardiovascular Disease: High-Dose Angiotensin II Type 1 Receptor Antagonist Monotherapy or Combination Therapy?

By Miura Shin-ichiro Saku Keijiro

American Journal of Cardiovascular Drugs, Vol. 8, Iss. 2, 2008-01 ,pp. : 88-90

Adis International

Access to resources Recommend Favorite

Angiotensin II receptor antagonists challenge ACE inhibitors

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 252, 2000-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Pharmacological characterization of EK112, a new combined angiotensin II and thromboxane A 2 receptor antagonist

By Hwang T.-L. Yeh Y.-A. Chern J.-W. Teng C.-M.

General Pharmacology, Vol. 34, Iss. 1, 2000-01 ,pp. : 25-31

Elsevier

Access to resources Recommend Favorite